According to Avalon Pharma (Middle East Pharmaceutical)'s latest financial reports the company's current EPS (TTM) is NZ$1.07. In 2025 the company made an earnings per share (EPS) of NZ$1.31 an increase over its 2024 EPS that were of NZ$1.08.